SINGAPORE, Dec 21 (Bernama-GLOBE NEWSWIRE) — ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today releases an open letter to shareholders from Chairman and Chief Executive Officer Sidney Chan. A copy of the letter is presented in this press release, the original can be found at https://alrt.com/investors/2021lettertoshareholders.
Dear Fellow Shareholders,
2021 has been a transformative year for ALRT within which we have accomplished many important milestones. Most notable is the formation of the animal health division. As discussed below, the successful launch of the GluCurve Pet CGM (Continuous Glucose Monitor) should lead to revenue, earnings, and positive cashflows in the second half of 2022. We have discussed partnership opportunities on the GluCurve Pet CGM with various interested pharmaceutical companies and have selected our top candidate and are targeting to finalize a definitive agreement by May 2022. Additionally, we have brought on key additions to the ALR Technologies corporate team, and we have laid the groundwork to revolutionize diabetes care in human health. I am grateful for the support of our current shareholders, and the interest we have received from potential institutional investors, investment funds, and retail investors alike.